Gesundheit · FDA panel · ArchivSechs gegen die Wissenschaftler: FDA-Gremium befürwortet Peptide ohne klinische ErfolgsbilanzVerfasst 7. September 2026 um 21:22 UTCAnsehenTranskript0:00The FDA's pharmacy compounding advisory0:02committee begins a critical two-day0:03meeting today in Washington to decide0:05whether to let compounding pharmacies0:07dispense seven unapproved peptide0:09substances that have exploded in0:10popularity on social media. At stake is0:12whether BPC 157, TB 500, and five other0:16peptides land on the section 503A bulk0:18drug substances list. Adding these to0:20the list wouldn't be FDA approval, but0:22it would allow licensed compounding0:24pharmacies to dispense them with a0:26prescription. FDA career scientists0:28recommended against every single one of0:30these substances, citing no human0:32clinical data for three of them. Three0:33of the seven have no human clinical data0:35at all. The other four have what the0:37agency calls inadequate data. Yet,0:39social media influencers on TikTok and0:41Reddit have driven soaring demand for0:42these substances, promoting them for0:44injury recovery, anti-aging, and0:46cognitive enhancement. That demand has0:48fueled a booming gray market. Peptide0:50imports from China reached $328 million0:53in 2025. Doctors warn patients are0:56buying unregulated versions online,0:58often injecting substances with unknown1:00purity and no clinical oversight. Dr.1:03Jessica Duncan, chief medical officer at1:05IVM Health, told the committee that1:07approving these substances without1:08clinical evidence amounts to an1:10experiment on the American public. Her1:12testimony reflects growing concern among1:13medical professionals. The push has1:15powerful backing. HHS Secretary Robert1:18F. Kennedy Jr. moved 14 of 19 previously1:21restricted peptides back to eligibility1:23in February, clearing the path for1:24today's vote. And the reconstituted1:26advisory panel now includes at least1:28eight members with financial ties to the1:30peptide industry. The committee is1:31expected to deliver its recommendation1:33by the end of the two-day meeting. Any1:36formal rulemaking that follows typically1:37takes 12 to 24 months, meaning the FDA1:40is unlikely to finalize new peptide1:43rules before the 2028 election cycle.Artikel lesenChronologie der GeschichteHeyDexDas Kurzvideo ↗
